Our points of view

"IML is clearly evolving towards its goal of being perceived as a responsible partner in the Grand Duchy of Luxembourg. This is thanks to the efforts of our Secretary General, but also to the energy of all of you. Thank you!"



Transparency in the interest of the patient.

Code of ethics

The Code of Ethics applies to all types of communication and interaction (traditional and digital) by our members.

Ethique dans nos pratiques

Ethics in our practices

Representing the innovative pharmaceutical industry, we are in contact with institutional, national and European actors in order to enable pharmaceutical innovations for Luxembourg patients. Transparency is at the heart of what we do.


e-PIL Pilot Project

The e-PIL pilot project started in August 2018 and aims to test the replacement of the paper patient information leaflet by the electronic leaflet in hospital drug packages in Belgium and Luxembourg.

It is supported by the Belgian and Luxembourg competent authorities and has been authorized by the European Commission.


Collaboration with patients

The patient's voice is central. Focus on our collaboration with Eupati Luxembourg.

Recherche _pexels

Drug Safety

Because patient safety is of the utmost importance to the innovative pharmaceutical industry, together with the other players in the field of medicines, we are a committed player in the implementation of an effective system for patients.

Become a member

Keep up to date with iml.lu

The flash letter informs you regularlay about the news of our sector in Luxembourg, the news of the research in Luxembourg, within our members and finally about the news of the association.  Don't waste a minute and subscribe.